Charles Schwab Investment Management Inc Akebia Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 586,710 shares of AKBA stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
586,710
Previous 568,667
3.17%
Holding current value
$1.23 Million
Previous $750,000
45.47%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding AKBA
# of Institutions
127Shares Held
56.5MCall Options Held
291KPut Options Held
179K-
Black Rock Inc. New York, NY11.6MShares$24.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$22.9 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.1 Million13.23% of portfolio
-
Geode Capital Management, LLC Boston, MA4.75MShares$9.98 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.72MShares$7.81 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $386M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...